公开(公告)号：US10551237B2

公开(公告)日：2020-02-04

申请号：US15726771

申请日：2017-10-06

Applicant: AIRBUS OPERATIONS LIMITED ,  ASTON UNIVERSITY

Inventor： Alessio Cipullo ,  Neil Thomson Gordon ,  Kaiming Zhou

IPC: G01B11/06 ,  G01F23/292

Abstract: A method of measuring a height of a fuel in an aircraft fuel tank (21)b including illuminating the fuel in the aircraft fuel tank and detecting reflected light from the fuel. Optical coherence tomography is used to determine the height of a surface of fuel in the fuel tank. An apparatus (30) is used to measure a height of a surface of fuel in an aircraft fuel tank, and an aircraft fuel tank system with a fuel tank and an apparatus for measuring a height of a surface of fuel in the aircraft fuel tank.

公开(公告)号：US20190002512A1

公开(公告)日：2019-01-03

申请号：US16131955

申请日：2018-09-14

Applicant: Aston University

Inventor： Michael J. Tisdale ,  Steven Russell

IPC: C07K14/47 ,  A61K45/06 ,  A61K9/00 ,  A61K31/138 ,  A61K47/61 ,  A61K47/60 ,  A23L33/17 ,  A61K38/17 ,  A61K31/137 ,  A61K38/26 ,  A61K38/28

Abstract: The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering Zn-α2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as β adrenergin receptor agonists, β adrenergin receptor antagonists, and/or glycemic control agents.

公开(公告)号：US20180339019A1

公开(公告)日：2018-11-29

申请号：US16058887

申请日：2018-08-08

Applicant: Aston University

Inventor： Michael J. Tisdale ,  Steven T. Russell

IPC: A61K38/17 ,  A61K31/138 ,  A61K31/195 ,  A61K45/06 ,  A61K31/135

Abstract: The invention provides compositions and methods for ameliorating symptoms associated with hyperglycemia by administering a Zn-α2-glycoprotein or a functional fragment thereof, methods of decreasing plasma insulin levels, methods of increasing skeletal muscle mass, and methods of bringing about a weight reduction or reduction in obesity. Also provided are pharmaceutical compositions for use thereof.

公开(公告)号：US20180302154A1

公开(公告)日：2018-10-18

申请号：US15762386

申请日：2016-09-22

Applicant: ASTON UNIVERSITY

Inventor： Filipe FERREIRA ,  Andrew ELLIS ,  Naoise MAC-SUIBHNE ,  Christian SANCHEZ-COSTA

IPC: H04B10/077 ,  H04J14/04 ,  H04Q11/00

CPC classification number: H04B10/0775 ,  H04J14/04 ,  H04Q11/0067

Abstract: A method of compensating for crosstalk in a mode division multiplexing passive optical network using a technique of transmitter-side crosstalk pre-compensation, performed at the Central Office, in which a downlink reference signal such as a training sequence or pilot signal is retrieved at the transmitter without being influenced by crosstalk effects on its uplink transmission. An uplink reference signal is transmitted in a quasi-single mode transmission along the optical fiber, and a plurality of optical signals input to transmission multiplexer are adapted based on the uplink reference signal to pre-compensate for crosstalk.

公开(公告)号：US20180050060A1

公开(公告)日：2018-02-22

申请号：US15559815

申请日：2016-03-16

Applicant: ASTON UNIVERSITY

Inventor： Meng CAI ,  Keqinq WANG ,  Asif AHMED

IPC: A61K31/713 ,  C12N15/11 ,  C12Q1/68 ,  G01N33/50

CPC classification number: A61K31/713 ,  C12N15/111 ,  C12N2310/113 ,  C12N2310/141 ,  C12N2320/30 ,  C12Q1/6883 ,  C12Q2600/118 ,  C12Q2600/178 ,  G01N33/50

Abstract: The invention provides a method of treating preeclampsia, fetal growth restriction (FGR or IUGR), obesity in pregnancy, post-partum cardiomyopathy (heart failure in mothers), cancer and diabetic retinopathy, cardiomyopathy, myocardial infarction, wet microdegeneration and other disorders where angiogenesis is aberrant either diminished or exacerbated, comprising modulating the activity of micro RNA (miRNA). Also provided are an MiRNA modulator or a combination thereof or functional fragments or homologues thereof for use in the treatment of preeclampsia, fetal growth restriction, obesity in pregnancy, cancer, and diabetic retinopathy, cardiomyocyte infarction, wet microdegeneration as well as other disorder where angiogenesis is aberrant either diminished or exacerbated. Methods of modulating angiogenesis and pharmaceutical compositions using miR-122, miR-374b or inhibitors of miR-152 or miR195 are also provided together with methods of diagnosis using the miRNAs.

公开(公告)号：US20170041078A1

公开(公告)日：2017-02-09

申请号：US15302573

申请日：2015-04-07

Applicant: Aston University

Inventor： Son Thai LE ,  Andrew ELLIS

IPC: H04B10/2543 ,  H04B10/61

CPC classification number: H04B10/2543 ,  H04B10/548 ,  H04B10/6163 ,  H04B2210/252

Abstract: A nonlinearity compensation technique for a CO-OFDM transmission system in which a proportion (e.g. up to 50%) of OFDM subcarriers is transmitted along with a phase-conjugate copy (PCP) on another subcarrier (replacing a data carrying subcarrier) to enable nonlinear distortion compensation. Nonlinear distortion experienced by closely spaced subcarriers in an OFDM system is highly correlated. The PCPs are used at the receiver to estimate the nonlinear distortion (e.g. nonlinear phase shift) of their respective original subcarriers and other subcarriers close to the PCP. With this technique, the optical fibre nonlinearity due to the Kerr effect in OFDM systems can be effectively compensated without the complexity of DBP or 50% loss in capacity of the phase conjugate twin wave (PC-TW) technique. Moreover, the technique proposed herein can be effectively implemented in both single polarization and PMD systems, in both single channel and WDM systems.

Abstract translation: 一种用于CO-OFDM传输系统的非线性补偿技术，其中OFDM子载波的比例（例如高达50％）与另一子载波上的相位共轭复制（PCP）一起发送（替代携带载波的数据载波）以实现非线性 失真补偿。 在OFDM系统中由紧密间隔的子载波经历的非线性失真是高度相关的。 在接收机处使用PCP来估计它们各自的原始子载波和靠近PCP的其他子载波的非线性失真（例如非线性相移）。 利用这种技术，可以有效地补偿OFDM系统中由于克尔效应引起的光纤非线性，而不需要DBP的复杂性或相位共轭双波（PC-TW）技术容量的50％损失。 此外，在单通道和WDM系统中，本文提出的技术可以在单极化和PMD系统中有效地实现。

公开(公告)号：US20150259310A1

公开(公告)日：2015-09-17

申请号：US14431472

申请日：2013-10-09

Applicant: ASTON UNIVERSITY

Inventor： Martin Griffin ,  Daniel Rathbone ,  Leonas Eduard Badarau

IPC: C07D295/26 ,  C07D295/205

CPC classification number: C07D295/26 ,  C07D233/84 ,  C07D295/185 ,  C07D295/205

Abstract: The present invention relates to novel compounds of Formula I capable of inhibiting tissue transglutaminase, and uses of the same in medicine. In particular, the invention provides compounds for use in the treatment of prevention of disease and conditions such as fibrosis (e.g. cystic fibrosis), scarring, neurodegenerative diseases (e.g. Alzheimer's disease, Huntington's disease and Parkinson's disease), autoimmune diseases (e.g. multiple sclerosis and coeliac disease), thrombosis, proliferative disorders (e.g. cancers), AIDS, psoriasis and inflammation (e.g. chronic inflammatory diseases).

Abstract translation: 本发明涉及能够抑制组织转谷氨酰胺酶的新型式I化合物及其在医药中的用途。 特别地，本发明提供了用于治疗疾病和病症例如纤维化（例如囊性纤维化），瘢痕形成，神经变性疾病（例如阿尔茨海默氏病，亨廷顿病和帕金森病），自身免疫性疾病（例如多发性硬化和 乳糜泻），血栓形成，增殖性疾病（例如癌症），AIDS，牛皮癣和炎症（例如慢性炎性疾病）。

公开(公告)号：US20140242089A1

公开(公告)日：2014-08-28

申请号：US14276957

申请日：2014-05-13

Applicant: Aston University

Inventor： Michael J. Tisdale ,  Penio T. Totorov

IPC: C07K16/18 ,  C07K14/47 ,  G01N33/574

CPC classification number: C07K16/18 ,  A61K38/00 ,  C07K14/47 ,  C07K14/473 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  G01N33/574 ,  G01N33/57488 ,  G01N2333/4728 ,  G01N2800/52

Abstract: A biologically active lipid mobilising agent for use in therapy is disclosed which has the properties and characteristics of a Zn-α2-glycoprotein, or of a fragment thereof having an apparent molecular mass Mr greater than 6.0 kDa as determined by gel exclusion chromatography. Methods of isolation and purification from biological material are also disclosed together with uses of the material for making up pharmaceutical compositions, especially pharmaceutical compositions useful for treating mammals to achieve weight reduction or for controlling obesity. In addition, uses of the material for developing diagnostic agents and for identifying inhibitors of lipolytic activity for therapeutic purposes are disclosed.

Abstract translation: 公开了一种用于治疗的生物活性脂质动员剂，其具有通过凝胶排阻色谱测定的具有大于6.0kDa的表观分子量Mr的Zn-α2-糖蛋白或其片段的性质和特征。 还公开了从生物材料分离和纯化的方法以及用于制备药物组合物的材料的用途，特别是可用于治疗哺乳动物以实现体重减轻或用于控制肥胖症的药物组合物。 此外，公开了用于开发诊断剂的材料和鉴定用于治疗目的的脂肪分解活性抑制剂的用途。

公开(公告)号：US20230090293A1

公开(公告)日：2023-03-23

申请号：US17909197

申请日：2021-02-24

Applicant: ASTON UNIVERSITY

Inventor： Jonathan COX ,  Nicolas BARRY ,  James HARRISON ,  Victoria NOLAN ,  Anaïs PITTO-BARRY ,  Joan SOLDEVILA-BARREDA

IPC: A61K31/7135 ,  A61K9/20 ,  A61K9/00 ,  A61K9/12 ,  A61P31/04

Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt; wherein L is a substituted or non-substituted aromatic ligand; Z is a halogen or coordinating ligand; M is a group 8 or group 9 transition metal selected from; Fe, Ru, Os, Co, Rh and Os; A and B are independently selected from a substituted or non-substituted indole or pyridine, may be the same or different and coordinate to the transition metal M through the nitrogen atom of the indole or pyridine. The compounds have been shown to have use against antibiotic-resistant bacteria. A further aspect of the invention is directed towards treating or preventing bacterial infections.

公开(公告)号：US11148111B2

公开(公告)日：2021-10-19

申请号：US15522422

申请日：2015-10-19

Applicant: ASTON UNIVERSITY

Inventor： Afzal-Ur-Rahman Mohammed ,  Eman Dahmash ,  Jiteen Ahmed ,  Thomas Drew

IPC: B01J2/12 ,  B01J2/00 ,  A23G3/26

Abstract: The present invention relates to an apparatus for coating carrier particles with guest particles. The apparatus comprises a cylindrical processing vessel rotatable about its axis and having solid walls defining a chamber for receiving the particles, and a hollow shaft extending within the chamber at least partly along the axis of the cylindrical processing vessel, the hollow shaft defining a gas flow path connected to a gas inlet. The hollow shaft comprises one or more axially-extending slots or one or more axially-extending rows of apertures allowing fluid communication between the gas flow path and the chamber. The apparatus may be used in a process for coating carrier particles with guest particles, the process comprising: adding the particles to the chamber defined by the cylindrical processing vessel; rotating the cylindrical processing vessel about its axis; and flowing gas from the gas inlet along the gas flow path in the hollow shaft and into the chamber through the one or more axially-extending slots or one or more axially-extending rows of apertures.